From GlobeNewswire: 2025-01-28 21:30:00

Akero Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 5,333,420 shares of its common stock at $48.00 per share, with expected gross proceeds of approximately $350.0 million. The offering is expected to close on January 30, 2025. J.P. Morgan, Morgan Stanley, and Jefferies are acting as joint book-running managers, with UBS Investment Bank as co-manager. Akero is a clinical-stage company developing treatments for metabolic diseases, including MASH. Forward-looking statements were included in the press release, cautioning about risks and uncertainties related to the offering and market conditions. Contact information for investors and media is provided.



Read more at GlobeNewswire: Akero Therapeutics Announces Pricing of Upsized Public